What is happening. Both tirzepatide and berberine can lower blood glucose through complementary mechanisms, creating a clinically important hypoglycemia risk when combined, especially if insulin or sulfonylureas are also used.
Mechanism. Tirzepatide activates GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, lowering glucagon, and slowing gastric emptying. Berberine activates AMPK and may improve insulin sensitivity and endogenous GLP-1 signaling. Combined glucose-lowering can be additive.
Recommendation. Do not add berberine to tirzepatide therapy without prescriber supervision. If both are used, monitor blood glucose closely during initiation and dose changes and carry fast-acting glucose.